Achillion Announces ACH-4471 Granted Orphan Drug Designation by the FDA and Positive Opinion for Orphan Drug Designation in the European Union for the Treatment of Paroxysmal Nocturnal Hemoglobinuria
06 nov. 2017 06h05 HE
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Nov. 06, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation...
Achillion Reports Third Quarter 2017 Financial Results and Provides Update on Clinical Programs
01 nov. 2017 16h05 HE
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today reported financial results for the three months ended September 30, 2017. For the third...
USPTO Grants Composition of Matter Patent to Achillion for ACH-4471, First-in-Class Small Molecule Complement Alternative Pathway Factor D Inhibitor
24 oct. 2017 06h05 HE
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Oct. 24, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that the U.S. Patent and Trademark Office (USPTO) has issued a U.S. Patent to...
Achillion Announces Presentation of Data From OMEGA-1 Phase 2b Trial With Odalasvir, AL-335, and Simeprevir (JNJ-4178) at the 2017 Liver Meeting
23 oct. 2017 07h00 HE
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Oct. 23, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) reported today Phase 2b data on JNJ-4178, the triple combination consisting of odalasvir, AL-335,...
Achillion to Present at the 2017 Leerink Partners Rare Disease Roundtable Series
20 sept. 2017 06h05 HE
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Sept. 20, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that members of the senior management team will provide a corporate update at the...
Achillion Announces Strengthening of Management Team
11 sept. 2017 03h02 HE
|
Achillion Pharmaceuticals, Inc.
- Mr. Joseph Truitt promoted to Chief Operating Officer - - Dr. Avner Ingerman joins as Head of Ophthalmology - NEW HAVEN, Conn., Sept. 11, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals,...
Achillion Announces Termination of Worldwide Collaboration for Hepatitis C With Janssen
11 sept. 2017 03h01 HE
|
Achillion Pharmaceuticals, Inc.
-Conference call to be held today at 9:00 a.m. ET- NEW HAVEN, Conn., Sept. 11, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that on Saturday, September 9,...
Achillion Reports Second Quarter 2017 Financial Results and Proof-of-Concept With a First-in-Class, Oral Factor D Inhibitor
08 août 2017 16h01 HE
|
Achillion Pharmaceuticals, Inc.
- Interim results demonstrate ability of ACH-4471 to reduce LDH and improve hemoglobin and fatigue scores in patients with untreated PNH - - Global program expansion planned in PNH, C3G and IC-MPGN -...
Achillion to Host Second Quarter 2017 Results Conference Call on August 8, 2017
01 août 2017 16h05 HE
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Aug. 01, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that it plans to report second quarter 2017 financial results on Tuesday, August 8,...
Achillion Pharmaceutials Announces Key Promotion and Discovery Organization Change
10 juil. 2017 16h05 HE
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., July 10, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), the leader in complement alternative pathway therapeutics, today announced that Mingjun Huang,...